Alfred L Garfall, Adam D Cohen, Sandra P Susanibar-Adaniya, Wei-Ting Hwang, Dan T Vogl, Adam J Waxman, Simon F Lacey, Vanessa E Gonzalez, Joseph A Fraietta, Minnal Gupta, Irina Kulikovskaya, Lifeng Tian, Fang Chen, Natalka Koterba, Robert L Bartoszek, Margaret Patchin, Rong Xu, Gabriela Plesa, Don L Siegel, Andrea Brennan, Anne Marie Nelson, Regina Ferthio, Angela Cosey, Kim-Marie Shea, Rachel Leskowitz, Megan Four, Wesley V Wilson, Fei Miao, Eric Lancaster, Beatriz M Carreno, Gerald P Linette, Elizabeth O Hexner, Regina M Young, Dexiu Bu, Keith G Mansfield, Jennifer L Brogdon, Carl H June, Michael C Milone, Edward A Stadtmauer
We conducted a phase 1 clinical trial of anti-BCMA CAR T cells (CART-BCMA) with or without anti-CD19 CAR T cells (huCART19) in multiple myeloma (MM) patients responding to third- or later- line therapy (Phase A, N=10) or high-risk patients responding to first-line therapy (Phase B, N=20), followed by early lenalidomide or pomalidomide maintenance. We observed no high-grade CRS and only one instance of low-grade neurologic toxicity. Among 15 subjects with measurable disease, 10 exhibited PR or better; among 26 subjects responding to prior therapy, 9 improved their response category and 4 converted to MRD-negative CR/sCR...
November 22, 2022: Blood cancer discovery